English | 简体中文 | 繁體中文 | 한국어
Orion Corporation and Fifth Corner Inc join forces to research solutions for improving the quality of life of prostate cancer patients

 Orion Corporation                                  Press release  4 January 2019 at 9.00 a.m.

Orion Corporation and Fifth Corner Inc join forces to research solutions for improving the quality of life of prostate cancer patients

Orion Corporation, a globally operating Finnish pharmaceutical company, and Fifth Corner Inc., a Finnish startup developing scalable digital coaching solutions, have initiated a collaborative research project to seek for new innovative solutions to help prostate cancer patients manage the stress caused by the devastating disease they have. The focus of the research is specifically aimed at finding new ideas and ways to improve the quality of life of the patients as well as understanding how the physical and mental stress that the patients are facing could be alleviated.

"The collaboration between Orion Corporation and Fifth Corner Inc kicked off from Orion's open innovation challenge facilitated by Vertical earlier in 2018. Ultimately the goal of this collaboration is to support patients living as active, normal and happy lives as possible. 'Before jumping into conclusions or developing any solutions, we really want to understand first what the prostate cancer patients are like. "We respect patients as individuals and want to create solutions that are specifically designed for them, appreciating their dreams and their needs", says Satu Ahomäki, Senior Vice President, Commercial Operations, Orion.

Prostate cancer is the second most common cancer in men. It usually progresses slowly and in most cases the patient does not die because of it. In other words, the patient may live with the disease for very long and experience both physical and mental stress in the different phases of treatment. In some cases the medical assessment may be that it's best to only follow up the progress without any treatments because the cancer is growing so slowly. However, research shows this approach can be even more stressful for the patient than getting treatment. Studies have also found that patients experience more anxiety and depression after treatment than during it. It's clear that prostate cancer patients need support no matter what their prognosis or treatment plan is.

Further information:

Satu Ahomäki, Senior Vice President, Commercial Operations, Orion Corporation
Tel. +358 (0)50 966 7616

Orion Corporation
Orionintie 1A, FI-02200 Espoo, Finland

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2017 amounted to EUR 1,034 million and the company had about 3,200 employees. Orion's A and B shares are listed on Nasdaq Helsinki

This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Oyj via Globenewswire

Copyright © Thomson Reuters 2019. All rights reserved.
Press Releases
AMG Advanced Metallurgical Group N.V. Announces Weekly Share Repurchase Program Transaction Details  
Apr 19, 2019 21:00 ET
SDLP - Seadrill Partners LLC receives early termination notice for the West Capricorn contract  
Apr 18, 2019 13:29 ET
CF&B Communication : Copenhagen May 16, 2019 - 30 listed companies, 40 institutional investors in One-to-One  
Apr 18, 2019 10:21 ET
Invitation to UPM's webcast and press conference on first quarter 2019 results  
Apr 18, 2019 09:00 ET
Nokia provides recast comparative segment results and additional financial disclosures for 2018 reflecting the new financial reporting structure  
Apr 18, 2019 08:01 ET
Lubrizol to Feature New Bio TPU Grades for 3D Printing and Molded Parts at Plastteknik Fair 2019  
Apr 17, 2019 22:59 ET
JCPenney Names New Principal Accounting Officer and Announces Key Strategic Executive Appointments  
Apr 17, 2019 19:59 ET
Lubrizol is Ready for ILSAC GF-6 - Announcing Lubrizol® PV1510 Additive Technology for the GF-6 Specification  
Apr 16, 2019 03:59 ET
Apr 15, 2019 22:29 ET
Lubrizol Showcases Renewable-Sourced Estane® 3D ECO TPU for 3D Printing at RAPID + TCT 2019  
Apr 12, 2019 20:29 ET
More News >>
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: